1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > Paroxysmal Nocturnal Hemoglobinuria Global Clinical Trials Review, H2, 2015

Paroxysmal Nocturnal Hemoglobinuria Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “Paroxysmal Nocturnal Hemoglobinuria Global Clinical Trials Review, H2, 2015" provides an overview of Paroxysmal Nocturnal Hemoglobinuria clinical trials scenario. This report provides top line data relating to the clinical trials on Paroxysmal Nocturnal Hemoglobinuria. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Paroxysmal Nocturnal Hemoglobinuria Global Clinical Trials Review, H2, 2015
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Report Guidance 4
Clinical Trials by Region 5
Clinical Trials and Average Enrollment by Country 6
Top Countries Contributing to Clinical Trials in Asia-Pacific 8
Top Five Countries Contributing to Clinical Trials in Europe 9
Top Countries Contributing to Clinical Trials in North America 10
Clinical Trials by G7 Countries: Proportion of Paroxysmal Nocturnal Hemoglobinuria to Hematological Disorders Clinical Trials 11
Clinical Trials by Phase in G7 Countries 12
Clinical Trials in G7 Countries by Trial Status 13
Clinical Trials by E7 Countries: Proportion of Paroxysmal Nocturnal Hemoglobinuria to Hematological Disorders Clinical Trials 14
Clinical Trials in E7 Countries by Trial Status 15
Clinical Trials by Phase 16
In Progress Trials by Phase 17
Clinical Trials by Trial Status 18
Clinical Trials by End Point Status 19
Subjects Recruited Over a Period of Time 20
Clinical Trials by Sponsor Type 21
Prominent Sponsors 22
Top Companies Participating in Paroxysmal Nocturnal Hemoglobinuria Therapeutics Clinical Trials 23
Prominent Drugs 24
Clinical Trial Profile Snapshots 25
Appendix 55
Abbreviations 55
Definitions 55
Research Methodology 56
Secondary Research 56
About GlobalData 57
Contact Us 57
Disclaimer 57
Source 58

List of Tables
Paroxysmal Nocturnal Hemoglobinuria Therapeutics, Global, Clinical Trials by Region, 2015* 5
Paroxysmal Nocturnal Hemoglobinuria Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 6
Paroxysmal Nocturnal Hemoglobinuria Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 7
Paroxysmal Nocturnal Hemoglobinuria Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015* 8
Paroxysmal Nocturnal Hemoglobinuria Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 9
Paroxysmal Nocturnal Hemoglobinuria Therapeutics Clinical Trials, North America, Top Countries, 2015* 10
Proportion of Paroxysmal Nocturnal Hemoglobinuria to Hematological Disorders Clinical Trials, G7 Countries (%), 2015* 11
Paroxysmal Nocturnal Hemoglobinuria Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 12
Paroxysmal Nocturnal Hemoglobinuria Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 13
Proportion of Paroxysmal Nocturnal Hemoglobinuria to Hematological Disorders Clinical Trials, E7 Countries (%), 2015* 14
Paroxysmal Nocturnal Hemoglobinuria Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 15
Paroxysmal Nocturnal Hemoglobinuria Therapeutics, Global, Clinical Trials by Phase, 2015* 16
Paroxysmal Nocturnal Hemoglobinuria Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 17
Paroxysmal Nocturnal Hemoglobinuria Therapeutics, Global, Clinical Trials by Trial Status, 2015* 18
Paroxysmal Nocturnal Hemoglobinuria Therapeutics Clinical Trials, Global, by End Point Status, 2015* 19
Paroxysmal Nocturnal Hemoglobinuria Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 20
Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 21
Paroxysmal Nocturnal Hemoglobinuria Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 22
Paroxysmal Nocturnal Hemoglobinuria Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 23
Paroxysmal Nocturnal Hemoglobinuria Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 24

List of Figures
Paroxysmal Nocturnal Hemoglobinuria Therapeutics, Global, Clinical Trials by Region (%), 2015* 5
Paroxysmal Nocturnal Hemoglobinuria Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 6
Paroxysmal Nocturnal Hemoglobinuria Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 7
Paroxysmal Nocturnal Hemoglobinuria Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2015* 8
Paroxysmal Nocturnal Hemoglobinuria Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 9
Paroxysmal Nocturnal Hemoglobinuria Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 10
Proportion of Paroxysmal Nocturnal Hemoglobinuria to Hematological Disorders Clinical Trials, G7 Countries (%), 2015* 11
Paroxysmal Nocturnal Hemoglobinuria Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 12
Paroxysmal Nocturnal Hemoglobinuria Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 13
Proportion of Paroxysmal Nocturnal Hemoglobinuria to Hematological Disorders Clinical Trials, E7 Countries (%), 2015* 14
Paroxysmal Nocturnal Hemoglobinuria Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 15
Paroxysmal Nocturnal Hemoglobinuria Therapeutics, Global, Clinical Trials by Phase (%), 2015* 16
Paroxysmal Nocturnal Hemoglobinuria Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 17
Paroxysmal Nocturnal Hemoglobinuria Therapeutics, Global, Clinical Trials by Trial Status, 2015* 18
Paroxysmal Nocturnal Hemoglobinuria Therapeutics Clinical Trials, Global, by End Point Status, 2015* 19
Paroxysmal Nocturnal Hemoglobinuria Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 20
Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 21
Paroxysmal Nocturnal Hemoglobinuria Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 22
Paroxysmal Nocturnal Hemoglobinuria Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 23
Paroxysmal Nocturnal Hemoglobinuria Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 24
GlobalData Methodology 56

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

  • $ 5650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The global clinical trial management system (CTMS) market is estimated to grow at a CAGR of 11.5% from 2016 to 2021, to reach USD 920.0 billion by 2021. The adoption of CTMS software is on the rise across ...

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global CRO services market is estimated to grow at a CAGR of 7.4% from 2016 to 2021, to reach USD 41.86 billion by 2021 from USD 29.29 billion in 2016. Growth in this market is primarily attributed ...

Clinical Trial Management System (CTMS) - Global Market Outlook (2016-2022)

Clinical Trial Management System (CTMS) - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • November 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Clinical Trial Management System (CTMS) market is expected to grow from $493.58 million in 2015 to reach $1118.58 million by 2022 with a CAGR of 12.4%. Huge research ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.